Cilostazol Versus Aspirin for Primary Prevention of Atherosclerotic Events (CAPPA)
Multi-Center, Randomized, Open Label Study of the Efficacy of Cilostazol Versus Aspirin for Primary Prevention of Atherosclerotic Events With Korean Type 2 DM Patients
Sponsor: Ajou University School of Medicine
Listed as NCT00886574, this PHASE4 trial focuses on Type 2 Diabetes Mellitus and remains ongoing. Sponsored by Ajou University School of Medicine, it has been updated 6 times since 2009, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Unknown PHASE4
-
Sep 2024 — Sep 2025 [monthly]
Unknown PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE4
Status: Unknown Status → Unknown
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status PHASE4
-
Jun 2018 — Jan 2021 [monthly]
Unknown Status PHASE4
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Unknown Status PHASE4
First recorded
Apr 2009
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Ajou University School of Medicine
- Hallym University Medical Center
- Hanyang University
- Inha University Hospital
- Inje University
- Korea University Guro Hospital
- Kyunghee University Medical Center
For direct contact, visit the study record on ClinicalTrials.gov .